You are here: Industry Insights > KRAS

News List

Amgen’s Lumakras Obtains Early FDA Approval for KRAS-Mutated NSCLC drugs
June 01, 2021
At the end of May, FDA approved Amgen’s Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer (NSCLC) whose tumors have a KRAS G12C genetic mutation and who have received at least one prior systemic therapy.
Verastem Oncology with Breakthrough Therapy for Defactinib in Ovarian Cancer americanpharmaceuticalreview
May 28, 2021
Results of Early Trial Demonstrate 70% Overall Response Rate (ORR) in Patients with KRAS Mutant Tumors, 44% ORR in KRAS Wild-Type Tumors and 52% ORR in All Evaluable Patients with a Favorable Safety Profile.
QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC) firstwordpharma
May 26, 2021
QIAGEN N.V. today announced MRTX to continue developing a tissue-based KRAS companion diagnostic to identify patients with cancers that have a KRASG12C mutation from treatment with adagrasib, Mirati's investigational
Elicio Announces IND for Vaccine Targeting Mutated KRAS Cancers americanpharmaceuticalreview
March 01, 2021
Elicio Therapeutics has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for ELI-002. ELI-002 is an Amphiphile (AMP) KRAS therapeutic vaccine containing AMP mKRAS peptides and a proprietary AMP CpG ...
CRUK scientists develop drug that targets KRAS pathways pharmatimes
January 05, 2021
A new study, funded by Cancer Research UK (CRUK) and Wellcome, has discovered a new way to target the KRAS mutation, which is found in a number of hard-to-treat cancer types.
Amgen announces global diagnostic collaborations worldpharmanews
January 14, 2020
Amgen announced strategic collaborations with leading diagnostic companies Guardant Health, Inc. and QIAGEN N.V. to develop blood- and tissue-based companion diagnostics (CDx), respectively, for investigational cancer treatment AMG 510.
Researchers use three-drug combination to treat lung cancer pharmaceutical-technology
September 26, 2019
A study by the Francis Crick Institute and The Institute of Cancer Research, London has tested the combination of a G12C KRAS inhibitor with mTOR and IGF1R inhibitors for the treatment of lung cancer.